Hancock Jaffe Laboratories Inc.
| NASDAQ: HJLI | Healthcare / Medical Devices & Instruments / USA |
| 5.89 | -0.4600 | -7.24% | Vol 283.97K | 1Y Perf -41.14% |
| Apr 15th, 2021 16:00 DELAYED |
| BID | 5.81 | ASK | 6.00 | ||
| Open | 6.40 | Previous Close | 6.35 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 28.00 | Analyst Rating | — 0.00 | |
| Potential % | 375.38 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 43.61 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 45.24 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 50.09M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 2.31 | Earnings Date | 6th Apr 2021 |
Today's Price Range 5.856.40 | 52W Range 5.5520.25 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -15.25% | ||
| 1 Month | -16.57% | ||
| 3 Months | -31.03% | ||
| 6 Months | -38.93% | ||
| 1 Year | -41.14% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 420.75 | |||
ROE last 12 Months | -238.34 | |||
ROA (5Y Avg) | -134.92 | |||
ROA last 12 Months | -136.48 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -145.08 | |||
Return on invested Capital Q | -72.23 | |||
Return on invested Capital Y | -198.32 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.90 | ||||
| 8.06 | ||||
| 191.44 | ||||
| - | ||||
| -8.50 | ||||
| -5.94 | ||||
| 8.06 | ||||
| 0.83 | ||||
| 48.78M | ||||
| Forward PE | -4.89 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.90 | ||||
| 3.00 | ||||
| 0.03 | ||||
| 0.12 | ||||
| 3.13K | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -24 247.00 | ||||
| -22 977.40 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -67.08 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | - | -1.50 | - |
| Q02 2020 | - | -2.00 | - |
| Q01 2020 | - | -1.50 | - |
| Q03 2019 | - | -2.50 | - |
| Q02 2019 | - | -0.13 | - |
| Q01 2019 | -0.27 | -0.13 | 51.85 |
| Q03 2018 | -0.68 | -0.13 | 80.88 |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2020 FY | -0.34 | 0.00 | - |
| 12/2021 FY | -1.42 | 62.43 | Positive |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 283.97K |
| Shares Outstanding | 8.50M |
| Trades Count | 1.93K |
| Dollar Volume | 4.68M |
| Avg. Volume | 597.53K |
| Avg. Weekly Volume | 303.54K |
| Avg. Monthly Volume | 473.36K |
| Avg. Quarterly Volume | 655.55K |
Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) stock closed at 5.89 per share at the end of the most recent trading day (a -7.24% change compared to the prior day closing price) with a volume of 285.19K shares and market capitalization of 50.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 12 people. Hancock Jaffe Laboratories Inc. CEO is Robert A. Berman.
The one-year performance of Hancock Jaffe Laboratories Inc. stock is -41.14%, while year-to-date (YTD) performance is -31.91%. HJLI stock has a five-year performance of %. Its 52-week range is between 5.55 and 20.25, which gives HJLI stock a 52-week price range ratio of 2.31%
Hancock Jaffe Laboratories Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 8.06, a price-to-sale (PS) ratio of 191.44, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -136.48%, a ROC of -145.08% and a ROE of -238.34%. The company’s profit margin is -%, its EBITDA margin is -22 977.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Hancock Jaffe Laboratories Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Hancock Jaffe Laboratories Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Hancock Jaffe Laboratories Inc. is — (0), with a target price of $28, which is +375.38% compared to the current price. The earnings rating for Hancock Jaffe Laboratories Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hancock Jaffe Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hancock Jaffe Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.53, ATR14 : 0.65, CCI20 : -173.90, Chaikin Money Flow : -0.21, MACD : -0.58, Money Flow Index : 74.35, ROC : -10.08, RSI : 29.43, STOCH (14,3) : 1.92, STOCH RSI : 0.00, UO : 38.49, Williams %R : -98.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hancock Jaffe Laboratories Inc. in the last 12-months were:
Hancock Jaffe Laboratories Inc.
Hancock Jaffe Laboratories Inc is a medical device company. It develops and sells biological tissue solutions to treat patients with coronary, vascular, end-stage renal and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices. Its key products include Bioprosthetic Heart Valve, CoreoGraft- Bypass Graft, and the Venous Valve.
CEO: Robert A. Berman
Telephone: +1 949 261-2900
Address: 70 Doppler, Irvine 92618, CA, US
Number of employees: 12
